XNAS
PPCB
Market cap5mUSD
Jul 09, Last price
1.78USD
1D
-1.11%
1Q
-30.87%
Jan 2017
-100.00%
IPO
-100.00%
Name
Propanc Biopharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
616.63%
Rev. gr., 5y
%
Revenues
0k
Net income
-59m
L+3,135.77%
CFO
-405k
L-56.67%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Propanc Biopharma, Inc. is an Australian biopharmaceutical company focused on developing cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancers. The firm's lead product, PRP, is a formulation in the preclinical phase designed to amplify the anti-cancer effects of multiple enzymes. Propanc engages in research collaborations, including a joint drug discovery program called POP1 with the University of Jaén, and a separate joint initiative with the Universities of Jaén and Granada to investigate changes in genetic and protein expression observed in cancer cells. Founded in 2007 and headquartered in Camberwell, Australia, the company was formerly known as Propanc Health Group Corporation before rebranding to Propanc Biopharma, Inc. in April 2017.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||